A new study has shown that impaired endogenous thrombolysis is a risk factor for cardiovascular events in patients with end-stage renal disease (ESRD). In 216 patients with ESRD followed up for an average of about 9 months, those with impaired endogenous thrombolysis (lysis time ≥3,000 s) were at increased risk of major adverse cardiovascular events (hazard ratio [HR] 4.25), nonfatal myocardial infarction and stroke (HR 14.28), and peripheral thrombosis (HR 9.08).